Myriad Genetics, MYGN

Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
Myriad Genetics (NASDAQ:MYGN – Get Free Report) had its price objective dropped by investment analysts at UBS Group from $18.00 to $16.00 in a note issued to investors on Tuesday,Benzinga reports. The ...
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results tomorrow after market hours. Here’s what you need to know. Myriad Genetics beat analysts’ revenue expectations ...
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors ...